Novavax | NVAX - Sales Revenues

Stock Price
10.11
Daily Change
0.88 9.53%
Monthly
18.38%
Yearly
69.21%
Q2 Forecast
9.90

Novavax reported $147.14M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Adma Biologics USD 114.5M 24.66M Mar/2026
Agenus USD 34.2M 3.97M Dec/2025
AstraZeneca USD 15.29B 213M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Geron USD 51.84M 3.82M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
MannKind USD 90.2M 21.76M Mar/2026
Merck USD 16.29B 110M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 389M 289M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
TG Therapeutics USD 194.8M 2.23M Mar/2026